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Edited by Gianni CesareniAbstract We have recently cloned the full-length cDNAs of the
two growth hormone secretagogue receptor (GHSR) subtypes
from a teleost species, the black seabream (Acanthopagrus
schlegeli) [Mol. Cell. Endocrinol. 214 (2004) 81], namely
sbGHSR-1a and sbGHSR-1b. Functional expression of these
two receptor constructs in human embryonic kidney 293
(HEK293) cells indicated that stimulation of sbGHSR-1a by
growth hormone secretagogues (GHS) could evoke increases in
intracellular Ca2+ concentration ([Ca2+]i), whereas sbGHSR-1b
appeared to play an inhibitory role on the signal transduction
activity of sbGHSR-1a. In the present study, we have further
investigated the signal transduction mechanism of sbGHSR-1a.
The peptide GHS GHRP-6 and the non-peptide GHS L163,540
were able to trigger a receptor speciﬁc and phospholipase C
(PLC)-dependent elevation of [Ca2+]i in HEK293 cells stably
expressing sbGHSR-1a. This GHS-induced calcium mobiliza-
tion was also dependent on protein kinase C activated L-type
calcium channel opening. It was found that sbGHSR-1a could
function in an agonist-independent manner as it exhibited a high
basal activity of inositol phosphate production in the absence of
GHS, indicating that the ﬁsh receptor is constitutively active. In
addition, the extracellular signal-regulated kinases 1 and 2
(ERK1/2) were found to be activated upon stimulation of
sbGHSR-1a by GHRP-6. This observation provides direct
evidence in the coupling of sbGHSR-1a to ERK1/2 activation.
Neither Gs nor Gi proteins are coupled to the receptor, as GHS
did not induce cAMP production nor inhibit forskolin-stimulated
cAMP accumulation in the sbGHSR-1a bearing cells. Further-
more, the ability of the GHSR antagonist D-Lys(3)-GHRP-6 to
inhibit basal PLC and basal ERK1/2 activity suggests that this
compound is an inverse agonist. In summary, the sbGHSR-1a
appears to couple through the Gq=11-mediated pathway to
activate PLC, resulting in increased IP3 production and Ca
2+
mobilization from both intracellular and extracellular stores.
Moreover, sbGHSR-1a may trigger multiple signal transduction
cascades to exert its physiological functions.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Growth hormone secretagogues (GHS) are small molecules
that can stimulate growth hormone (GH) secretion in a
number of vertebrate species [1–6]. These GHS exert their
physiological actions via activation of a G-protein coupled
receptor (GPCR) called growth hormone secretagogue recep-
tor (GHSR) [7–9]. In mammals, GHSR is mainly located in the
pituitary and hypothalamus [10], but signiﬁcant levels are also
found in peripheral tissues [11]. It was, therefore, hypothesized
that GHS could take part in diverse physiological actions
apart from controlling GH secretion. For example, it has now
been shown that the GHS system is involved in a number of
physiological functions including the control of energy ex-
penditure [12,13], the quality of sleep [14], pancreatic functions
and glucose metabolism [15], gastric acid secretion [16], and
cardiovascular activity [17].
In view of its diverse physiological roles, the signaling
mechanism of GHSR has attracted much research interest and
large species diﬀerence in the signal transduction mechanism of
the receptor has been noticed. In rat somatotrophs, GHS could
induce the accumulation of inositol triphosphate (IP3) and
activate protein kinase C (PKC) leading to an increase of in-
tracellular calcium concentration ([Ca2þ]i) [18,19]. On the
other hand, the action of GHS on ovine somatotrophs was
found to depend mainly on the production of cAMP in which
activation of PKC potentiates the protein kinase A (PKA)
cascade causing GH secretion [20]. PKC activation and cAMP
production have also been observed in human acromegalic
tumor cells by GHRP-2, but the cAMP-PKA pathway does
not seem to be essential for the GHS-induced GH secretion in
these cells [21]. In all these reports, the experiments have been
performed in primary culture of cells obtained from pituitary
glands or pituitary tumors. It is, therefore, not certain whether
the activation of both the cAMP-PKA and the phospholipase
C (PLC)-PKC pathways by GHS is the result of direct GHSR
activation or via cross-talk with other receptors or with other
signaling pathways in the cells. In order to better elucidate the
signaling events in a cleaner system, cultured cell lines ex-
pressing speciﬁc receptor constructs are necessary.
We have previously identiﬁed two transcripts of GHSR from
a teleostean species, the black seabream Acanthopagrus schle-
geli, namely sbGHSR-1a which is a classical GPCR with 7-
transmembrane domains and GHSR-1b which is a truncated
receptor containing 5-transmembrane domains with no known
signaling activity [22]. The sbGHSR-1a shares a low degree ofblished by Elsevier B.V. All rights reserved.
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from the mammalian situation, the expression of these recep-
tors in seabream is restricted to the pituitary and some other
brain parts only, with expression in the peripheral tissues being
extremely low. If species diﬀerence in the GHSR signaling
events is apparent even among the mammalian GHSRs in
which the sequences are more than 90% identical with each
other, the elucidation of the signaling mechanism of the ﬁsh
GHSR would be highly warranted from a phylogenetic point
of view, since the ﬁsh receptor shares only about 60% identity
with the mammalian GHSRs. Moreover, we found that the
functional activity of sbGHSR-1a could be attentuated by the
co-expressed sbGHSR-1b, but it is not yet known whether
the sbGHSR-1b exerts its modulatory role by interfering with
the signal transduction pathway of sbGHSR-1a. Further in-
vestigations on how the two receptors interact will only be
possible when we have a better understanding on how the
functional sbGHSR-1a couples to cell signaling pathways. The
present report thus aims to study the pharmacological proﬁle
and receptor-eﬀector coupling system of the sbGHSR-1a in
cultured human embryonic kidney 293 (HEK293) cells. Re-
sults obtained would shed light on the signaling mechanism of
the teleostean GHSR and would also provide the basis for
further studies on the molecular mechanism of how sbGHSR-
1b regulates sbGHSR-1a activity.2. Materials and methods
2.1. Materials
All the materials used in cell culture were obtained from Invitrogen
(Carlsbad, CA, USA) unless otherwise stated. GHRP-2, GHRP-6 and
ipamorelin were purchased from Neosystem (Strasbourg, France). The
GHSR antagonist, D-Lys(3)-GHRP-6, was purchased from Bachem
(Bubendorf, Switzerland). The non-peptide GHS L163,540 was a gift
from Dr. Roy Smith of the Merck Research Laboratories (Rathway,
USA). Nitrendipine was purchased from Calbiochem (La Jolla, CA,
USA). U73122, phorbol-12-myristate-13-acetate (PMA) were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). U0126 and all the
antibodies used were purchased from Cell Signaling Technology
(Beverly, MA, USA). The [3H]myo-inositol was purchased from NEN
Life Sciences Products (Boston, MA, USA). [3H]adenine was pur-
chased from Amersham Biosciences (Piscataway, NJ, USA).
2.2. Cell culture and development of a clonal cell line stably expressing
sbGHSR-1a
A clonally selected HEK293 cell line stably expressing sbGHSR-1a
(HEK-sbGHSR-1a) was developed as previously described [22] and
was maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
containing 500 lg/ml G418.
2.3. Intracellular calcium mobilization assay
Intracellular calcium mobilization in HEK-sbGHSR-1a cells in-
duced by various GHS was measured as described previously [22],
using Fluo-4 AM (Molecular Probes, Eugene, OR, USA) on a Wallac
Victor2 multilabel plate reader (Perkin–Elmer Life Sciences, Boston,
MA, USA) at kEx ¼ 485 nm and kEm ¼ 535 nm. The values of the
ﬂuorescence increase were calculated as the peak ﬂuorescence value
minus the basal level.
2.4. [3H]inositol phosphate accumulation assay
HEK-sbGHSR1a cells were seeded in 12-well culture plates pre-
treated with 0.01% (w/v) poly-D-lysine (Sigma–Aldrich). After an
overnight incubation (16–20 h) with [3H]myo-inositol (1 lCi/ml; spe-
ciﬁc activity 10–25 Ci/mmol), the medium was aspirated and the cells
washed with HEPES-buﬀered saline (HBS) (15 mM HEPES, pH 7.4,
140 mM NaCl, 4.7 mM KCl, 2.2 mM CaCl2, 1.2 mM MgCl2, 1.2 mM
KH2PO4, and 11 mM glucose) followed by 10 min incubation at 37 C
in HBS containing 20 mM LiCl. The buﬀer was removed and replacedwith fresh buﬀer and the cells were incubated, in duplicates, with HBS
or 100 lM D-Lys(3)-GHRP-6 for 15 min. Then, the cells were incu-
bated with diﬀerent concentrations of agonists for a further 60 min,
and the reaction was terminated by aspiration and addition of ice-cold
20 mM formic acid. The plates were left on ice for at least 60 min
before separating the [3H]inositol phosphates from the total radio-
active inositol fraction by column chromatography as described
previously [23].
2.5. [3H]cAMP accumulation assay
[3H]cAMP accumulation was measured by seeding HEK-sbGHRS-
1a cells in 12-well culture plates pre-treated with 0.01% (w/v) poly-D-
lysine. After an overnight incubation (16–20 h) with [3H]adenine (1
lCi/well; speciﬁc activity 27 Ci/mmol), the medium was aspirated and
the cells were washed with HBS. They were then incubated with the
test compounds dissolved in HBS containing 1 mM 3-isobutyl-1-
methyl xanthine at 37 C for 30 min. The reaction was terminated by
aspiration and addition of ice-cold 5% trichloroacetic acid containing
1 mM ATP. [3H]cAMP accumulation was assessed by determining
the ratio of [3H]cAMP to total [3H]adenine nucleotides as described
previously [24].
2.6. Measurement of ERK1/2 activity using Western blots
Twenty hours before the assay, the HEK-sbGHSR1a cells were se-
rum-starved in 6-well plates. The cells were then pre-treated with either
control buﬀer (HBS) for 30 min, 100 lM D-Lys(3)-GHRP-6 for 15 min
or 10 lMU0126 for 30 min at 37 C. Control buﬀer or 5 lMGHRP-6
was then added and the cells were incubated for a further 15 min be-
fore the assay was terminated by cell lysis on ice for 30 min (Cell lysis
buﬀer: 50 mM Tris base, pH 7.5, 0.1 M NaCl, 5 mM EDTA, 67 mM
sodium pyrophosphate, 0.01% Triton X-100, 0.2 mM phenylmethyl-
sulfonyl ﬂuoride, 0.2 mM sodium orthovanadate, 1 mM dithiothreitol,
4 lM leupeptin and 4 lg/ml aprotinin). The cell lysates were then
centrifuged at 12 000 g for 15 min at 4 C. Equal amounts of lysates
(30–50 lg/lane) were separated by SDS–PAGE on a 12% gel and
electrophoretically transferred onto Hybond nitrocellulose membranes
(Amersham Biosciences). The membranes were then incubated with
anti-phospho-ERK1/2 (anti-pERK1/2) antibody or anti-ERK1/2 an-
tibody overnight at 4 C. Immunoblots were developed by horseradish
peroxidase-linked goat anti-rabbit immunoglobulin and an ECL
chemiluminescence kit (Amersham Biosciences). The band intensity
was quantiﬁed using the computer program Scion Image (Scion
Corporation, Frederick, USA).
2.7. Data analysis
pEC50 values were calculated by ﬁtting the log concentration–re-
sponse curves by standard non-linear regression analysis using Prism
3.0 (GraphPad Software, San Diego, USA). The production of
[3H]inositol phosphates was determined as the ratio of radiolabeled
inositol phosphates to total inositol and was expressed as percentage
conversion [(inositol phosphates)/(total inositol) 100%]. [3H]cAMP
accumulation was also calculated as percentage conversion and is ex-
pressed as fold induction relative to the control (HBS treatment). All
data are expressed as mean values SEM from three or more inde-
pendent experiments. The data were considered statistically signiﬁcant
at P < 0:05 using either unpaired t test, or one-way ANOVA followed
by Tukey’s multiple comparison test or Newman–Keuls test.3. Results
3.1. Activation of sbGHSR-1a leads to changes in [Ca2þ]i
GHRP-6 evoked an elevation of [Ca2þ]i in HEK-sbGHSR-
1a cells (Fig. 1), which was typiﬁed by a rapid initial peak
(maximal at approximately 20 s after the addition of the ag-
onist) followed by a gradual decline to a plateau level for up to
at least 3 min. The peak response represented an almost
doubling of the basal unstimulated level.
The ability of sbGHSR-1a to elevate [Ca2þ]i was charac-
terized using the three synthetic GHS (Table 1). All the
agonist-induced [Ca2þ]i elevations were log concentration-
dependent with the potency in the following order: ipamore-
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Fig. 2. The role of extracellular Ca2þ in GHS-induced calcium mobi-
lization in HEK-sbGHSR-1a cells. Panel A is the time-course of
[Ca2þ]i elevation upon stimulation by 30 lM GHRP-6 in the presence
(Panel A1) or absence (Panel A2) of extracellular Ca2þ. Panel B is the
time-course of [Ca2þ]i elevation upon stimulation by 30 lM L163,540
in the presence (Panel B1) or absence (Panel B2) of extracellular Ca2þ.
Panel C is the eﬀect of nitrendipine on the GHRP-6- and L163,540-
induced [Ca2þ]i elevation. P < 0:01; P < 0:001.
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Fig. 1. A time-course study of [Ca2þ]i elevation in HEK-sbGHSR-1a
cells stimulated by 30 lMGHRP-6. The arrow indicates the time when
GHRP-6 was introduced.
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induced by GHRP-6 as the standard, the relative eﬃcacy
of L163,540 was the highest, followed by GHRP-6 and
ipamorelin.
3.2. Extracellular Ca2þ and L-type Ca2þ channels are involved
in sbGHSR-1a activation
Although GHRP-6 and L163,540 could still elicit some in-
creases in [Ca2þ]i in the absence of extracellular Ca2þ (Fig. 2,
panels A2 and B2), the magnitudes of the responses were much
reduced when compared with the situation in which extracel-
lular Ca2þ was present. Furthermore, the responses were more
transient in nature and returned to the basal level within 90 s,
as opposed to a more sustained response in the presence of
extracellular Ca2þ.
The above results indicated that calcium channels were ac-
tivated during the course of sbGHSR-1a signaling. This was
substantiated by the fact that pre-treatment of HEK-sbGHSR-
1a cells by the L-type calcium channel blocker nitrendipine for
30 min signiﬁcantly inhibited the GHRP-6 and L163,540-
induced increases in [Ca2þ]i (Fig. 2C).
3.3. Activation of sbGHSR-1a leads to changes in [3H]inositol
phosphate production
Both GHRP-6 and L163,540 produced log concentration-
dependent increases in [3H]inositol phosphate production in
HEK-sbGHSR-1a cells (Fig. 3A) with EC50 values of 3.63 and
0.17 lM, respectively (Table 2). Pre-treatment of HEK-
sbGHSR-1a cells for 15 min with the GHSR-1a antagonist D-
Lys(3)-GHRP-6 shifted the log concentration-response curves
of GHRP-6 and L163,540 to the right (Fig. 3A), giving esti-
mated pA2 values of 4.33 0.12 and 4.29 0.15, respectively.Table 1
Ability of various synthetic GHS to increase [Ca2þ]i in HEK-sbGHSR-
1a cells
Agonist pEC50 Intrinsic activity Hill coeﬃcient
GHRP-6 5.48 0.09 100 1.82 0.34
L163,540 6.24 0.08 145 14 1.71 0.19
Ipamorelin 6.50 0.07 76 8 1.81 0.26
Basal ﬂuorescence in the absence of agonist was 3990 102 U. Max-
imum response to GHRP-6 was 7422 113 U. Values are mean
values SEM (n ¼ 6).Notably, the basal PLC activity was signiﬁcantly higher in
HEK-sbGHSR-1a cells than that of the parental HEK293
cells, suggesting that the sbGHSR-1a is a constitutively active
receptor (Table 2). This high basal PLC activity in the HEK-
sbGHSR-1a cells could also be signiﬁcantly decreased by the
GHSR antagonist D-Lys(3)-GHRP-6.
3.4. GHS-induced [Ca2þ]i elevation is PLC- and
PKC-dependent
The GHS-mediated PLC activation was further demon-
strated to be crucial for the agonist-induced [Ca2þ]i elevation,
as pre-treatment of HEK-sbGHSR-1a cells with the PLC
Table 2
GHS-stimulated increases in [3H]inositol phosphate production in HEK-sbGHSR-1a cells
GHS agonist antagonist pEC50 Hill coeﬃcient Basal activity
(% conversion)
Maximum response
(% conversion)
GHRP-6 alone 5.44 0.06 1.47 0.47 6.50 1.29 69.72 11.14
GHRP-6+D-Lys(3)-GHRP-6 4.94 0.07 1.27 0.27 4.35 1.98 67.68 7.09
L163,540 alone 6.78 0.16 2.31 0.61 5.29 2.32 70.10 11.60
L163,540+D-Lys(3)-GHRP-6 6.29 0.25 1.35 0.35 3.35 1.49 68.54 9.41
The peptide GHS agonist (GHRP-6) and the non-peptide GHS agonist (L163,540) were tested, either alone or after pre-treatment with 100 lMGHSR
antagonist (D-Lys(3)-GHRP-6). Values are mean valuesSEM (n ¼ 6). P < 0:05 vs basal activity. The basal activity of the parental HEK293 cells
without the expressed receptor was 0.69 0.05% conversion (n ¼ 5).
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Fig. 3. GHS-induced [Ca2þ]i elevation in HEK-sbGHSR-1a cells is PLC-PKC-dependent. Both GHRP-6 (s) and L163,540 () cause a log con-
centration-dependent increase in [3H]inositol phosphate ([3H]IP) production in HEK-sbGHSR1a cells. Pre-treatment of the cells with 100 lM D-
Lys(3)-GRHP-6 (d) shifted the log concentration-responsive curves to the right (Panel A). Inhibition of PLC by U73122 (Panel B) and inhibition of
PKC by PMA (Panel C) decreased the GHS (30 lM)-induced [Ca2þ]i increase in HEK-sbGHSR-1a cells, P < 0:01; P < 0:001.
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induced increases in [Ca2þ]i (Fig. 3B). To investigate the role of
PKC in mediating the GHS-stimulated increases in [Ca2þ]i,
HEK-sbGHSR-1a cells were incubated for 24 h with PMA to
downregulate the PKC activity. Calcium mobilization in re-
sponse to GHRP-6 and L163,540 was signiﬁcantly inhibited by
PMA pre-treatment (Fig. 3C). However, the proﬁle of the
GHS-induced [Ca2þ]i elevation was not changed in the pres-
ence of either inhibitor (data not shown).
3.5. Activation of sbGHSR-1a does not lead to changes in
[3H]cAMP production
Neither GHRP-6 nor L13,540 produced any change in
[3H]cAMP production in HEK-sbGHSR-1a cells, indicating a
lack of coupling of sbGHSR-1a to Gs proteins (Fig. 4). The
adenylate cyclase activator forskolin increased [3H]cAMP ac-
cumulation to 24.9 3.0 fold basal. This increase in adenylate
cyclase activity was neither aﬀected by GHRP-6 nor L163,540,indicating a lack of coupling of sbGHSR-1a to Gi-proteins
(Fig. 4).
3.6. Phosphorylation of extracellular signal-regulated kinases
(ERK1/2) is a signaling event of GHS activation of
HEK-sbGHSR-1a cells
GHRP-6 produced a 4-fold activation of ERK1/2 in HEK-
sbGHSR-1a cells (Fig. 5). Pre-treatment of cells with the
GHSR antagonist D-Lys(3)-GHRP-6 inhibited both basal and
GHRP-6-stimulated ERK1/2 activity by about 40% and 55%,
respectively. The MEK inhibitor U0126 abolished the GHRP-
6-induced phosphorylation of ERK1/2 (Fig. 5).4. Discussion
Receptor interaction was demonstrated in the two previ-
ously cloned GHSRs from the seabream pituitary, in which
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Fig. 4. Eﬀect of HBS, forskolin (100 lM), GHRP-6 (30 lM) and
L163,540 (30 lM) on [3H]cAMP accumulation in HEK-sbGHSR-1a
cells.
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ated GHS induced [Ca2þ]i [22]. Because of this receptor in-
teraction and because of the co-existence of both receptors in
the seabream pituitary, the use of seabream pituitary cells is
therefore not preferable for studying the signaling of sbGHSR-
1a due to the complexities involved. Thus, the use of a re-
combinant expression system in transfected cultured cells,
which has been demonstrated to be a powerful tool in a wide
variety of species [25–28], provides a cleaner system to perform
the signaling studies. The HEK293 cell was chosen because this
cell line contains no endogenous GHSR-1a [22].
Stimulation by both peptide and non-peptide GHS elicited a
log concentration-dependent increase in [Ca2þ]i in HEK-
sbGHSR-1a cells, but the potency of these GHS was less thanFig. 5. Eﬀect of GHRP-6 on ERK1/2 phosphorylation in HEK-
sbGHSR1a cells. Both the GHSR antagonist D-Lys(3)-GHRP-6 (100
lM) and the MEK inhibitor U0126 (10 lM) signiﬁcantly decreased the
GHRP-6 (5 lM)-induced ERK1/2 phosphorylation. The Western blot
shown underneath the graph is a representative result from three in-
dependent experiments (pERK1/2: phosphorylated ERK1/2; tERK1/2:
total ERK1/2). P < 0:05; P < 0:01.that shown in previous human GHSR-1a studies [8]. This is
not surprising as the synthetic GHS were developed to act best
on the human GHSR. The endogenous ligand for human
GHSR-1a, ghrelin, was also demonstrated to be a weak
stimulator of HEK-sbGHSR-1a cells, as detectable signals
could only be recorded when 10 lM ghrelin (data not shown)
was used. Attempts to quantify the receptor density of
sbGHSR-1a in HEK-sbGHSR-1a cells using commercially
available iodinated human ghrelin failed, conﬁrming that hu-
man ghrelin has a very low aﬃnity towards sbGHSR-1a.
Further investigations on the activity of the natural ligand
await identiﬁcation of the endogenous seabream ghrelin.
Both the peptide and non-peptide GHS stimulated a bi-
phasic elevation of [Ca2þ]i in HEK-sbGHSR-1a cells. The
sbGHSR-1a thus appears to couple through the Gq=11-
mediated pathway to activate PLC, resulting in increased IP3
production and Ca2þ mobilization from intracellular stores
(the initial transient elevation in [Ca2þ]i) and from extracellu-
lar sources via L-type Ca2þ channels (the plateau phase of the
elevated [Ca2þ]i). Similar results have been observed in rat and
human pituitary cells showing that the L-type Ca2þ channel
was involved in GHSR-1a-induced Ca2þ mobilization [29,30].
This L-type Ca2þ channel is in fact found in a wide range of
cell types and is particularly involved in endocrine cells for
hormone secretion [31]. In teleosts, the activation of L-type
Ca2þ channels was reported to be a pre-requisite for GH se-
cretion from the somatotrophs [32,33]. It is thus postulated
that the GHS-mediated GH secretion in seabream pituitary
probably also involves activation of the L-type Ca2þ channels.
On the other hand, the GHS-induced [Ca2þ]i response was
slow in onset in rat skeletal muscle and was not blocked by
nifedipine or the removal of external Ca2þ [34], suggesting that
the L-type Ca2þ channels may not be essential for GHSR
signaling in non-pituitary tissues.
In rat somatotrophs, PLC and PKC activation is essential
for the GHRP-6 induced GH secretion [35]. GHS also in-
creased phosphoinositide turnover, causing the translocation
of PKC in rat and human pituitary cells [19,36]. In the present
study, we have demonstrated that inhibition of either PLC or
PKC in HEK-sbGHRS-1a cells attenuated GHS-stimulated
increases in [Ca2þ]i. Furthermore, activation of sbGHSR-1a
appears to cause a PKC-dependent opening of L-type Ca2þ
channels. If the Ca2þ channels were activated by Ca2þ released
from intracellular stores, then inhibition of PKC would not
decrease the GHS-stimulated increase in [Ca2þ]i as shown in
Fig. 3C. Recently, Camina et al. [37] showed that ghrelin-
induced calcium mobilization was unchanged after PKC in-
hibition by PMA treatment in HEK293 cells expressing human
GHSR-1a. This result is very diﬀerent from our observations
shown in the present study as well as those reported by Bres-
son-Bepoldin and Dufy-Barbe [18] in rat pituitary. It is not
known at present what accounts for this species diﬀerence in
the role of PKC in GHS-induced calcium mobilization, and
further investigations are warranted.
In ovine somatotrophs, GHRP-2 stimulation caused an ac-
cumulation of cAMP [38] and it has been suggested that
adenylate cyclase-PKA is the major signal transduction path-
way for GHS in the ovine pituitary [20]. A similar situation
was reported in human acromegalic tumor cells in which
GHRP-2 increased cAMP production [21]. However, it is un-
certain whether the GHS-mediated cAMP accumulation in the
above studies is GHSR-speciﬁc, since there are other receptor
152 C.-B. Chan et al. / FEBS Letters 577 (2004) 147–153types in the pituitary. The possibility that receptor subtypes
other than GHSR-1a and GHSR-1b [39] are activated by GHS
to trigger the observed cAMP accumulation cannot be ruled
out. Studies on sbGHSR-1a signal transduction reported
herein show no evidence for the activation or inhibition of
adenylate cyclase activity, providing direct evidence, at least in
seabream, that GHSR-1a does not aﬀect adenylate cyclase.
During the preparation of this manuscript, Carreira et al. [40]
reported a similar ﬁnding that human GHSR-1a expressed in
HEK293 cells did not trigger cAMP production when stimu-
lated by ghrelin. In view of the fact that previously obtained
results on the species diﬀerences in GHSR signaling have been
conducted in primary cells from tissues, a revisit of the sig-
naling mechanism by transfection of the receptor constructs in
cultured cell lines is highly warranted.
Interestingly, the HEK-sbGHSR-1a cells display a relatively
high level of basal [3H]inositol phosphate production when
compared with the parental HEK293 cells. This basal PLC
activity could be signiﬁcantly inhibited by the GHSR-1a an-
tagonist D-Lys(3)-GHRP-6 (Table 2), suggesting that
sbGHSR-1a can function in an agonist-independent manner
and that D-Lys(3)-GHRP-6 is an inverse agonist. This high
GHSR-1a basal activity found in seabream, together with the
recent ﬁnding that the human GHSR-1a is also a constitutively
active receptor [41], indicates that some aspects of GHSR have
been conserved during evolution, in terms of the receptor–
eﬀector coupling systems.
Previous studies have demonstrated that receptors which
stimulate PLC via coupling to Gq=11 proteins can activate ex-
tracellular signal-regulated kinases (ERK) [42,43]. Although
studies on H9c2 cardiomyocytes showed that both ghrelin and
des-ghrelin inhibited doxorubicin-induced apoptosis via ERK
and Akt serine kinase, it has been suggested that the anti-ap-
optosis eﬀect of ghrelin is mediated through a novel GHSR
subtype rather than the classical GHSR-1a [44]. It is also not
clear whether the ability of ghrelin to activate insulin receptor
substrate-1, phosphatidylinositol 3-kinase and mitogen-
activated protein kinase (MAPK) in hepatoma cells is
GHSR-1a speciﬁc or not [45]. The eﬀect of GHS on the
phosphorylation of ERK1/2 in HEK-sbGHSR-1a cells was
therefore studied. It is evident from our results that the
GHRP-6-induced ERK1/2 phosphorylation reported herein is
a GHSR-1a speciﬁc response, as the presence of the GHSR
antagonist could signiﬁcantly inhibit the ERK1/2 phosphory-
lation. These results suggest that sbGHSR-1a has a potential
to trigger multiple signal transduction pathways of which one
is the MAPK cascade. However, it remains unknown whether
there is any cross-talk between the PLC-PKC pathway and the
MAPK cascade. Moreover, the biological consequences of
the ERK1/2 phosphorylation after stimulation of GHSR still
remain to be elucidated.
In summary, sbGHSR-1a is a constitutively active receptor
which triggers a PLC-PKC-dependent calcium mobilization in
HEK293 cells when activated by either peptide or non-peptide
GHS. This calcium mobilization also depends on the opening
of L-type calcium channels activated by PKC. Seabream
GHSR-1a activation also leads to ERK1/2 phosphorylation
for which the biological signiﬁcance remains to be elucidated.Acknowledgements: We thank Dr. Roy Smith of Merck Research
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